NCT07153770 is a Phase 2 clinical trial of Bozitinib in NSCLC, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT07153770?

NCT07153770 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT07153770?

Interventions in NCT07153770: Bozitinib.

What condition does NCT07153770 study?

NCT07153770 studies NSCLC, MET Exon 14 Mutation, MET Activating Mutation.

Is NCT07153770 still recruiting?

NCT07153770 is currently not yet recruiting. Last updated 4 September 2025.

Last reviewed 2025-09-04 · How we verify

NCT07153770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

Not yet recruiting Phase 2 Last updated 4 September 2025

What this trial tests

Phase 2 trial testing Bozitinib in NSCLC in 34 participants. Not yet recruiting.

Timeline

20 September 2025

Primary endpoint
20 September 2027

20 September 2028

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	20 September 2025
Primary completion	20 September 2027
Estimated completion	20 September 2028

Drugs / interventions tested

Bozitinib — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →
MET Exon 14 Mutation — all drugs for MET Exon 14 Mutation →
MET Activating Mutation — all drugs for MET Activating Mutation →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

18 and older, any sex, with NSCLC or MET Exon 14 Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aim to evaluate the efficacy and safety of Bozitinib combined with chemotherapy as radical treatment for stage IIA-IIIC MET-altered non-small cell lung cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies.
Hao S, Zhao S, Shi L, Zhong L, et al · · 2026 · PMID 41816478 · DOI 10.21037/jtd-2025-aw-2202

Verify or expand the search:

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07153770 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 4 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07153770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing